Accessibility helpSkip to navigationSkip to contentSkip to footer
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign In
  • Home
  • World
    Sections
    • World Home
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    Most Read
    • Nine killed and thousands injured as Hizbollah pagers explode in Lebanon
    • Exploding pagers join long history of killer communications devices
    • Draghi is trying to save Europe from itself
    • Why Europe will not catch up with the US
    • Kamala Harris admits she still has ‘to earn’ the Black male vote
  • US
    Sections
    • US Home
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
    Most Read
    • Why Europe will not catch up with the US
    • Kamala Harris admits she still has ‘to earn’ the Black male vote
    • US dollar trades in the doldrums as rates and data weigh on outlook
    • US delays decision on Nippon Steel’s $15bn takeover of US Steel
    • Chevron boss blames Biden for pushing up energy prices
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • The fury of the frequent flyer
    • BlackRock and Microsoft plan $30bn fund to invest in AI infrastructure
    • EU competition chief warns against weakening rules to create champions
    • Steve Cohen to step back from trading at hedge fund Point72
    • Reeves orders crackdown on government use of consultants
  • Tech
    Sections
    • Tech Home
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
    Most Read
    • BlackRock and Microsoft plan $30bn fund to invest in AI infrastructure
    • Meta faces hefty EU antitrust fine over classified ads practices
    • ‘No Man’s Sky’ and ‘Cyberpunk 2077’ show there is life after death for video-game flops
    • Amazon orders staff back to office five days a week
    • Data centres must work ‘within climate limits’, says Irish minister
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
    Most Read
    • BlackRock and Microsoft plan $30bn fund to invest in AI infrastructure
    • Steve Cohen to step back from trading at hedge fund Point72
    • Switzerland’s SIX explores launching crypto exchange
    • BP’s US wind sale will not clear its strategic fog
    • Chevron boss blames Biden for pushing up energy prices
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • The fury of the frequent flyer
    • Why Europe will not catch up with the US
    • Charlie Mullins is back on Pimlico Plumbers’ home turf
    • Draghi is trying to save Europe from itself
    • Market speculation about the next Fed rate cut masks deeper issues
  • Lex
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
    Most Read
    • FT and Schroders Business Book of the Year 2024 — the shortlist
    • Amazon orders staff back to office five days a week
    • Tata chair on ‘painful’ transitions: ‘We have to do this’
    • Italy retains allure for rich Europeans fleeing higher taxes
    • Belleville rising: a weekend in Paris’s hip and hilly 20th arrondissement
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Thoroughly modern Mayfair
    • ‘No Man’s Sky’ and ‘Cyberpunk 2077’ show there is life after death for video-game flops
    • Why every man needs a smart black hoodie
    • The brothers trying to save the British fountain pen
    • Ralph Steadman interview: ‘The harshness of my work is the softness in me’
  • HTSI
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Lex
  • Work & Careers
  • Life & Arts
  • HTSI
Financial Times
SubscribeSign In

Dementia

  • Friday, 30 August, 2024
    Personal Finance
    Reader callout: are you concerned about social care costs?

    Care home costs have been rising steeply

  • Wednesday, 28 August, 2024
    Patients on diabetes drugs less likely to develop dementia, research finds

    More trials urged as part of effort to slow cognitive declines with existing medicines

    A woman with diabetes monitors her blood glucose level
  • Wednesday, 28 August, 2024
    John Hardy
    The disappointing Alzheimer’s decision is part of a bigger problem

    Nice’s ruling on lecanemab demonstrates the lack of readiness to roll out new treatments in the UK

    Alzheimer’s Drug lecanemab / Leqembi
  • Thursday, 22 August, 2024
    Alzheimer’s drug approved by UK regulator but too costly for NHS

    Spending watchdog declines to give green light to lecanemab for patients in England

    R. Scott Turner, Professor of Neurology and Director of the Memory Disorder Center at Georgetown University Hospital, points to PET scan results that are part of a study on Alzheimer's disease at Georgetown University Hospital. The PET scans show images labeled with different markers: Amyloid-β (PiB) and Tau (T807), with conditions noted as Clinically Normal and Alzheimer's Dementia.
  • Wednesday, 31 July, 2024
    High cholesterol critical factor in development of dementia, study finds

    Reducing 14 ‘modifiable’ risks can prevent or delay cognitive disorder, report says

    Doctor reviewing MRI scans
  • Friday, 26 July, 2024
    Pharmaceuticals sector
    European Medicines Agency rejects breakthrough Alzheimer’s drug

    Eisai and Biogen face uphill battle to win EU approval for Leqembi after committee’s ruling

    Bottles and packages of the drug Leqembi
  • Thursday, 25 July, 2024
    Shingles vaccine ‘may prevent dementia’, research finds

    GSK’s Shingrix is latest drug to show potential for targeting previously untreatable brain disorders

    Shingrix shingles vaccine
  • Monday, 8 July, 2024
    InterviewThe CEO
    ‘I saw a massive opportunity for what this organisation could be’: Hilary Evans-Newton on transforming Alzheimer’s Research UK

    Decision to associate charity with a cure turned it into Europe’s biggest funder of dementia research

    Hilary Evans-Newton
  • Tuesday, 2 July, 2024
    Pharmaceuticals sector
    Eli Lilly wins US approval for early-stage Alzheimer’s treatment

    New drug Kisunla will be 20% more than rival as drugmaker claims it requires fewer treatments

    Eli Lilly sign on company’s offices
  • Monday, 10 June, 2024
    Eli Lilly & Co
    Eli Lilly’s Alzheimer’s drug wins backing of US advisory panel

    Independent experts conclude unanimously that the experimental treatment is effective

    A doctor looks at a PET brain scan
  • Monday, 13 May, 2024
    Takeda Pharmaceutical Co Ltd
    Takeda reaches $2bn deal to develop Alzheimer’s vaccine

    Japanese pharma group takes on new jab that makes immune system attack dangerous protein build-up in brain

    A yellow, green and purple cross-section of the brain can be seen in the image, against a blue background
  • Monday, 22 April, 2024
    News in-depth
    Alzheimer’s drug Leqembi falls short of blockbuster status in faltering US rollout

    High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval

    Carolyn Davis at her Pensacola Beach home
  • Wednesday, 20 March, 2024
    Drugs research
    UK dementia adviser wants half a million volunteers for clinical trials

    Ruth McKernan aims to make country a hub for research into the condition and accelerate development of new drugs

    Ruth McKernan
  • Thursday, 14 March, 2024
    Health
    Nervous system disorders found to be biggest cause of poor health

    Worldwide study finds neurological conditions affect billions as life expectancy rises

    Person looks at computer screens showing brain scans
  • Friday, 8 March, 2024
    Eli Lilly & Co
    US regulator delays decision on Eli Lilly’s Alzheimer’s drug

    Breakthrough medicine will now be subject to further review by committee of independent experts

    Eli Lilly signage on a building
  • Friday, 8 March, 2024
    House & Home
    Whose house is it, anyway? The growing problem of inheritance

    With ageing populations and dementia rates rising fast, the family home — worth more than ever before — is increasingly the focus of discord

  • Wednesday, 21 February, 2024
    Serious MoneyClaer Barrett
    Banks need to wake up to powers of attorney demands

    Research by Which? reveals huge disparity between the best and the worst

  • Monday, 12 February, 2024
    Blood protein test offers ‘reliable’ Alzheimer’s warning 15 years early

    Large study further boosts fast-evolving efforts to predict and prevent neurogenerative diseases

    A neurologist holds an MRI scan of a human head
  • Monday, 29 January, 2024
    Alzheimer’s was passed between humans in now-banned procedure, study finds

    Cases connected to growth hormone extracted from cadavers show disease’s parallels with CJD brain disorder

    Someone holding up a brain scan
  • Monday, 22 January, 2024
    Medical science
    Blood test boosts hopes of early Alzheimer’s diagnosis

    Swedish trial finds ‘high accuracy’ in identifying protein associated with toxic build-up in the brain

    A finger points at a brain scan
  • Friday, 19 January, 2024
    News in-depthInheritance
    England’s courts see rise in the number of inheritance disputes

    Boom in asset prices and increased prevalence of dementia drive costly family squabbles over wills

  • Tuesday, 31 October, 2023
    The FT ViewThe editorial board
    Glimmers of hope in tackling dementia

    Further research on its underlying causes and preventive action is essential

    A scientist looks at brain scans on a computer screen
  • Monday, 30 October, 2023
    The Big Read
    What is behind the unexpected decline in dementia?

    Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer

  • Wednesday, 25 October, 2023
    Drugs research
    New studies find benefits in very early drug treatment of Alzheimer’s

    Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier

    Screen showing brain patterns of an Alzheimer’s patient
  • Sunday, 8 October, 2023
    UK biotech group raises £48mn for Alzheimer’s research

    AstronauTx’s financing is step towards helping millions of people suffering from disease

Previous page You are on page 1 Next page

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookie PolicyManage CookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsProfessional SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on XFT ChannelsFT Schools

Tools

PortfolioFT AppFT Digital EditionFT EditAlerts HubBusiness School RankingsSubscription ManagerNews feedNewslettersCurrency Converter

Community & Events

FT Live EventsFT ForumsBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2024. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Edition:International
UK
Subscribe for full access

Top sections

  • Home
  • World
    • Israel-Hamas war
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
  • US
    • US Economy
    • Investing in America
    • US Companies
    • US Politics & Policy
    • US Presidential Election 2024
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
    • Artificial intelligence
    • Semiconductors
    • Cyber Security
    • Social Media
  • Markets
    • Alphaville
    • Markets Data
    • Crypto
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Wealth Management
    • Moral Money
    • ETF Hub
    • Fund Management
    • Trading
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Lex
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Europe's Start-Up Hubs
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    • Working It
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • HTSI
  • Special Reports

FT recommends

  • Alphaville
  • FT Edit
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • Visual and data journalism
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Live Events
  • FT Forums
  • Board Director Programme
  • myFT
  • Portfolio
  • FT Digital Edition
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In